It looks like nothing was found at this location. Maybe try one of the links below or a search?
Try looking in the monthly archives. 🙂
Faecal Calprotectin is a new biomarker which is helping to save money for the NHS by preventing unnecessary procedures on patients by screening out patients with IBS who do not require endoscopies.
The symptoms of functional disorders such as Irritable Bowel Syndrome (IBS) and organic inflammatory intestinal disease (IBD) can be very similar in presentation but are two very different medical conditions.
The Workflow Revolution Continues for Serum Calprotectin June 29, 2023
New Presentation Format for UK NEQAS April 8, 2022
Point-of-Care Calprotectin Testing Just Got Easier with New and Improved Quantum Blue® III March 17, 2021
New App Helps Bowel Disease Patients Monitor Their Own Treatment February 24, 2021
NICE DG56 vs. NICE DG30 - Updates to FIT Guidance
In 2023 @nicecomms published updated guidance on Quantitative Faecal Immunochemical Testing (#FIT) to guide #colorectalcancer pathway referral in #primarycare. Take a look at the changes here: https://a.storyblok.com/f/93856/x/f73766825f/nice-dg56-vs-nice-dg30.pdf
New Leading Edge Just Launched🚀
Articles include:
- Next Level CALEX® Workflow Revolution
- Serum Calprotectin Analysis: ELISA vs. Turbidimetric Assays
- NICE DG56 vs. NICE DG30: Updates to FIT Guidance
Read now: https://files.alphalabs.co.uk/e-mags/Leading_Edge_2024-Issue-1/ #ClinicalDiagnostics #HealthcareInnovation